zyversa therapeutics inc 2025年季度报告

For the quarterly period endedMarch 31,2025 For the transition period from _________to_________ Commission File Number:001-41184 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdictionof incorporation or organization)2200 N. Commerce Parkway,Suite 208 (Address of principal executive offices) (754)231-1688 For the Three Months Ended March 31, 2024 For the Three Months Ended March 31,20252024Cash Flows From Operating Activities: Stock-based compensation72,291Issuance of common stock pursuant to vendor agreements81,600Depreciation of fixed assets-Non-cash rent expense- Operating lease liability-Accrued expenses and other current liabilities445,061 Cash Flows From Financing Activities: Private placement of warrants1,999,791Registration and issuance costs associated with warrant issuance(147,131) Net Increase / (Decrease) in Cash80,608(1,104,098)Cash - Beginning of Period1,530,9243,137,674 Supplemental Disclosures of Cash Flow Information:Warrant modification - incremental value$53,890$ The accompanying notes are an integral part of these condensed consolidated financial statements.4 Note 1 –Business Organization, Nature of Operations and Basis of Presentation Organization and Operations ZyVersa Therapeutics, Inc. (“ZyVersa” and the “Company”) is a clinical stage biopharmaceutical company leveraging proprietarytechnologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs.The Company’s mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.Basis of Presentation and Principles of Consolidation the Company as of March 31, 2025 and for the three months ended March 31, 2025 and 2024. The results of operations for the threemonths ended March 31, 2025 are not necessarily indicative of the operating results for the full year. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notesthereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2024, filed with the Securities andExchange Commission (“SEC”) on March 27, 2025. Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments andassumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financialstatements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believesare reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common sharesoutstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted averagenumber of common and dilutive common-equivalent shares outstanding during each period. The following table presents the March 31,20252024Numerator:Net loss attributable to common stockholders$(2,256,930)$(2,826,737 The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: For the Three Months EndedMarch 31,20252024[1]3,852,2589,603Series A Convertible Preferred Stock72Series B Convertible Preferred Stock2,067 Segment Reporting The Company has one operating and reporting segment (clinical stage biopharmaceutical), namely, the development of drugs forpatients with chronic renal or inflammatory diseases with high unmet medical needs. The accounting policies of the segment are the Company’s chief executive officer, utilizes the Company’s financial information on an aggregate, consolidated basis for purposes ofmaking operating decisions, allocating resources and assessing financial performance, as well as for making strategic operations Disclosures (Subtopic 220 – 04). This update requires an entity to disclose more detailed information regarding expenses for the entity.The amendments require that at each interim and the annual reporting period, the entity must disclose amounts related to purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Including the amounts, the entity is required todisclose and qualitative description of the amounts remaining in relevant expense captions, and to disclose the total amount of sellingexpenses and the definition of selling expenses. The amendments in this update should be applied prospectively to financial statementsissued for reporting periods, and retrospectively to any prior periods presented in the financials. Although early adoption is permitted,the new guidance becomes effective for annual reporting